Healthy ham
A collaborating team of investigators1 based in Spain, Japan and the UK believe they may have discovered the potential health benefits of Spanish dry-cured ham. They consider that the ham could reduce high blood pressure associated with cardiovascular disease when consumed as part of a healthy diet.
A collaborating team of investigators1 based in Spain, Japan and the UK believe they may have discovered the potential health benefits of Spanish dry-cured ham. They consider that the ham could reduce high blood pressure associated with cardiovascular disease when consumed as part of a healthy diet.
The investigators fractionated water-soluble peptides from the ham samples taken from the ham by size-exclusion chromatography (SEC) followed by reversed-phase high performance liquid chromatography (RP-HPLC). Nano-liquid chromatography coupled to mass spectrometry was used to analyse a total of 73 peptides selected from bioactive fractions. The anti‑hypertensitivity of candidate peptides was quantified; notably, the majority of the candidates were of skeletal muscle origin. The in vitro activity of peptides was measured by testing inhibition of the enzymatic activity of angiotensin I converting enzyme (ACE). ACE is a common target for clinical inhibitors used for reducing hypertension. The in vivo hypertensive activity was measured by observing the effect of administering candidate peptides to hypertensive rats.
The unique peptide profile identified is hypothesized to be the result of an accumulation of fragment by-products of endogenous muscle enzyme break-down during the treatment of the ham that would otherwise not be present.
The team’s results suggest that the presence of the anti‑hypertensive peptides may off-set the adverse effects of the high levels of sodium chloride on blood pressure. Moreover, studies to elucidate the mechanism of action may lead to advances in drug discovery and development.
1. E. Escudero et al, Journal of Proteomics, (http://dx.doi.org/10.1016/j.jprot.2012.10.019)(2012).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
